Treatment Advances

December 05, 2024

FDA reviews belantamab mafodotin for relapsed multiple myeloma, the decision is expected by July 2025.

November 28, 2024

Learn how BRCA gene mutations affect myeloma risk. Learn why genetic testing could be crucial for younger patients and those with family cancer history.

November 14, 2024

Learn about the microenvironment and how certain treatments target myeloma cells' interaction with the cells around them. 

November 12, 2024

Johnson & Johnson seeks FDA and EMA approval for Darzalex Faspro in high-risk smoldering myeloma, aiming to change the treatment paradigms.

November 07, 2024

Learn what newly diagnosed multiple myeloma patients need to know about how induction (starting) therapy is evolving in the myeloma treatment landscape.

October 18, 2024

Learn what two recent studies have to say about who could possibly come off their maintenance therapy and for how long they could stay off.

October 17, 2024

Learn how findings from the International Myeloma Society 2024 meeting highlight the challenges and future consideration of MGUS and smoldering myeloma.

September 23, 2024

The FDA has approved isatuximab (Sarclisa) with VRd as a first-line treatment for newly diagnosed multiple myeloma patients who are not eligible for transplant.

September 16, 2024

Learn how the CAR-Enhancer platform improves CAR T-cell therapy durability and outcomes for relapsed multiple myeloma patients.

September 13, 2024

Explore promising new myeloma therapies like CAR-T, bispecific antibodies, and emerging targets beyond BCMA for relapse treatment and improved outcomes.